NASDAQ:MITO - Stealth BioTherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $3.00
  • Forecasted Upside: 112.77 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.41
▼ -0.01 (-0.70%)

This chart shows the closing price for MITO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Stealth BioTherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MITO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MITO

Analyst Price Target is $3.00
▲ +112.77% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Stealth BioTherapeutics in the last 3 months. The average price target is $3.00, with a high forecast of $3.00 and a low forecast of $3.00. The average price target represents a 112.77% upside from the last price of $1.41.

This chart shows the closing price for MITO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Stealth BioTherapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/25/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/1/2021Maxim GroupInitiated CoverageBuy$3.00High
5/20/2021HC WainwrightReiterated RatingBuyLow
5/8/2020HC WainwrightReiterated RatingBuy$5.00 ➝ $4.00Low
4/14/2020Roth CapitalInitiated CoverageBuy$9.00High
4/3/2020Nomura SecuritiesLower Price TargetBuy$14.00 ➝ $10.00High
4/2/2020BMO Capital MarketsBoost Price TargetMarket Perform$3.00 ➝ $7.00High
4/2/2020HC WainwrightUpgradeNeutral ➝ Buy$5.00Medium
2/18/2020Cantor FitzgeraldReiterated RatingOverweight$7.00 ➝ $10.00High
12/23/2019HC WainwrightDowngradeBuy ➝ Neutral$21.00 ➝ $5.00High
12/20/2019BMO Capital MarketsDowngradeOutperform ➝ Market Perform$7.00High
11/15/2019HC WainwrightReiterated RatingBuy$21.00High
10/18/2019HC WainwrightSet Price TargetBuy$21.00High
10/18/2019Nomura SecuritiesSet Price TargetBuy$28.00N/A
10/15/2019Jefferies Financial GroupSet Price TargetHold$9.00Low
10/8/2019HC WainwrightReiterated RatingBuy$30.00High
9/27/2019Cantor FitzgeraldInitiated CoverageOverweight$18.00High
7/12/2019HC WainwrightReiterated RatingBuy$30.00High
6/18/2019HC WainwrightInitiated CoverageBuy$30.00High
3/12/2019Jefferies Financial GroupInitiated CoverageHold ➝ Hold$16.00High
3/12/2019Nomura SecuritiesInitiated CoverageBuy ➝ Buy$23.00High
3/12/2019Evercore ISIInitiated CoverageOutperform ➝ Outperform$35.00High
3/12/2019BMO Capital MarketsInitiated CoverageOutperform$29.00High
(Data available from 10/18/2016 forward)

News Sentiment Rating

0.55 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/20/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/19/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/18/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/18/2021

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Stealth BioTherapeutics logo
Stealth BioTherapeutics Corp. is a clinical-stage biotechnology company, which engages in the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. The company was founded on April 3, 2006 and is headquartered in George Town, Cayman Islands.
Read More

Today's Range

Now: $1.41
Low: $1.40
High: $1.44

50 Day Range

MA: $1.33
Low: $1.17
High: $1.48

52 Week Range

Now: $1.41
Low: $1.06
High: $2.58

Volume

56,300 shs

Average Volume

1,962,049 shs

Market Capitalization

$81.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Stealth BioTherapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Stealth BioTherapeutics in the last year: HC Wainwright, Maxim Group, and Zacks Investment Research.
View the latest analyst ratings for MITO.

What is the current price target for Stealth BioTherapeutics?

1 Wall Street analysts have set twelve-month price targets for Stealth BioTherapeutics in the last year. Their average twelve-month price target is $3.00, suggesting a possible upside of 112.8%. Maxim Group has the highest price target set, predicting MITO will reach $3.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $3.00 for Stealth BioTherapeutics in the next year.
View the latest price targets for MITO.

What is the current consensus analyst rating for Stealth BioTherapeutics?

Stealth BioTherapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MITO will outperform the market and that investors should add to their positions of Stealth BioTherapeutics.
View the latest ratings for MITO.

How do I contact Stealth BioTherapeutics' investor relations team?

Stealth BioTherapeutics' physical mailing address is 275 GROVE STREET SUITE 3-107, NEWTON MA, 02466. The company's listed phone number is 617-600-6888 and its investor relations email address is [email protected] The official website for Stealth BioTherapeutics is www.stealthbt.com.